Behind the Consultant Curtain: Leveraging Your Segment’s Strengths

Posted by Malik Kaman on Jan 8, 2018 8:00:00 AM

Maria Whitman and Sankalp Sethi co-wrote this blog post with Malik Kaman. This blog post is part two in a two-part series.

In our previous post, we discussed the four typical “segments” of oncology companies:

  1. Original Innovators: High prior oncology success, low commercial sophistication
  2. The Space Invaders: Low prior oncology success, high commercial sophistication
  3. The New Kids on the Block: Low prior oncology success, low commercial sophistication
  4. The Vanguard: High prior oncology success, high commercial sophistication

>
Read More

Going Beyond the Buzz of CAR-T Therapy

Posted by Robert Rovner on Dec 21, 2017 10:21:09 AM

There’s no doubt that chimeric antigen receptor T-cell (CAR-T) therapies have been generating increased interest over the past four years at the American Society of Hematology’s (ASH) Annual Meeting. In 2014, 34 abstracts on CAR-T therapies were presented at ASH, a number that more than tripled to 110 abstracts by 2016. This year, more than 140 CAR-T abstracts were presented to a packed Georgia World Congress Center in Atlanta. While some questions about this novel approach to cancer treatment remain unanswered, one thing is for certain: CAR-T therapies are here to stay. 


>
Read More

Multiple Myeloma at ASH 2017: Observations and Analysis

Posted by Josh Hattem on Dec 14, 2017 9:11:58 AM

There were 935 abstracts related to multiple myeloma accepted into the 2017 American Society of Hematology (ASH) Annual Meeting, or roughly one piece of new research for every 127 multiple myeloma patients in the U.S., according to the National Cancer Institute.


>
Read More

Behind the Consultant Curtain: What Kind of Oncology Company Are You?

Posted by Malik Kaman on Dec 12, 2017 2:21:03 PM

Maria Whitman and Sankalp Sethi co-wrote this blog post with Malik Kaman. This blog post is part one in a two-part series.

At ZS, we’ve advised companies on more than 90% of the launches in oncology over the past five years, so manufacturers frequently ask us how they compare to others in terms of their people, their processes and their capabilities. This is a great question. With the pace of oncology investment worldwide—oncology is expected to be 21.25% of total pharma sales in 2020 globally, according to a Quintiles analysis—the level of competition in this space has risen to a whole new level. As we think about what it will take to compete and win in the new reality, it’s important to consider the commercial advantages and disadvantages of who you are as a company—your people, processes and capabilities—not just what scientific innovations you can bring.


>
Read More

Improving Drug Development: A Call to Action

Posted by Malik Kaman on Nov 9, 2017 9:39:46 AM

Joe Keller, Chris Crabtree and Sarah Jegasothy co-wrote this article with Malik Kaman. 

If you’ve missed the transformation of the oncology therapeutic landscape over the past five years, you’ve had your head in the sand. While many recent advancements are hugely beneficial, one result of this tidal wave of investment is that some new drugs offer only marginal improvements yet command outrageous price tags. This is a controversial issue and should give everyone in oncology pause. 


>
Read More